title: Clinical response and tolerability of fampridine in clinical practice.
abstract: BACKGROUND
  Gait disorder is very prevalent in multiple sclerosis. After 15 years of disease progression, 50% of patients need assistive devices for walking.
  
  
  METHODS
  We performed a multicenter observational study, including multiple sclerosis patients with an Expanded Disability Status Scale score between 4.0 and 7.0, normal kidney function and no previous history of seizures.
  
  
  RESULTS
  The study sample comprised 138 patients with average age of 50.3 years median Expanded Disability Status Scale of 6.0. After treatment, a significant reduction was observed in both the Timed 25-Foot Walk test (baseline, 20.3 s; 14 days, 13.2 s; p < 0.001; 3 months, 12.1 s; p < 0.001) and the 12-Item Multiple Sclerosis Walking Scale score (baseline, 82.3; 14 days, 59.4; p < 0.001; 3 months, 57.2; p < 0.001). Adverse events were recorded in 39.9% of patients.
authors.affiliation: Department of Neurology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: Costa-Arpín
authors.affiliation: Department of Neurology, Hospital POVISA, Vigo, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Pato
authors.affiliation: Department of Neurology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Rodríguez-Regal
authors.affiliation: Department of Neurology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain.
authors.forename: Luciana
authors.initials: L
authors.lastname: Midaglia
authors.affiliation: Department of Neurology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain.
authors.forename: Rosa
authors.initials: R
authors.lastname: Yáñez
authors.affiliation: Department of Neurology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain.
authors.forename: Delicias
authors.initials: D
authors.lastname: Muñoz
authors.affiliation: Department of Neurology, Hospital POVISA, Vigo, Spain.
authors.forename: José R
authors.initials: JR
authors.lastname: Lorenzo
authors.affiliation: Department of Neurology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain.
authors.forename: Campo
authors.initials: C
authors.lastname: Amigo
authors.affiliation: Department of Neurology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: José M
authors.initials: JM
authors.lastname: Prieto
mesh_terms: D015761:4-Aminopyridine / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004244:Dizziness / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D020233:Gait Disorders, Neurologic / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D026902:Potassium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D016138:Walking / Q000502:physiology
chemical_list: D026902:Potassium Channel Blockers; D015761:4-Aminopyridine
keywords: efficacy; gait disorder; multiple sclerosis; prolonged-release fampridine; safety